Approved indications
• Acromegaly in adults who are not adequately controlled with or cannot have surgery or radiation.
• Adult patients with unresectable, well‑ or moderately‑differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP‑NETs) to slow tumor growth.
• Carcinoid syndrome: to reduce the frequency of severe diarrhea and flushing episodes in adults when used with short‑acting octreotide as needed for breakthrough symptoms.

Off‑label uses and evidence
• Sometimes used off‑label for other neuroendocrine tumors (for example, some lung NETs) and for symptom control in hormone‑secreting tumors when somatostatin analogs are appropriate; evidence typically comes from small trials, observational studies, or extrapolation from GEP‑NET data.
• Choice between lanreotide and other somatostatin analogs (such as octreotide LAR) often depends on tumor type, receptor expression, prior response, and practical factors (formulation and injection technique) rather than strong head‑to‑head efficacy differences.

Efficacy expectations
• Acromegaly: reductions in growth hormone and IGF‑1 may be seen within weeks, with improvement in symptoms (headache, sweating, soft‑tissue swelling) often developing over several weeks to months; many patients achieve biochemical control or meaningful reduction, but some require combination therapy or surgery/radiation.
• GEP‑NETs: studies show prolongation of progression‑free survival and tumor stabilization for many patients; complete shrinkage is less common, but disease control is typical when tumors express somatostatin receptors.
• Carcinoid syndrome: bowel movement frequency and flushing episodes often begin to improve within days to weeks of initiation; some patients continue to need short‑acting octreotide for breakthrough symptoms.
• Compared with similar long‑acting somatostatin analogs, overall efficacy for controlling hormone‑related symptoms and slowing progression is generally similar, with differences mainly in dosing schedule, injection method, and individual patient response.

Typical dosing and administration
• Given as a deep subcutaneous injection, usually in the upper outer buttock, by a healthcare professional using a prefilled syringe.
• Acromegaly: common starting dose is about 90 mg every 4 weeks, with adjustments (typically 60–120 mg) based on growth hormone/IGF‑1 levels and symptoms.
• GEP‑NETs and carcinoid syndrome: a typical dose is 120 mg every 4 weeks; dosing may be individualized based on tumor control and symptom response.
• Injections are not tied to meals or time of day but should be given on a consistent schedule.

Special dosing instructions
• Dose adjustments may be needed in some patients with moderate or severe kidney or liver impairment, per product‑specific recommendations.
• For carcinoid syndrome, short‑acting octreotide may be continued as needed to handle breakthrough flushing or diarrhea, especially early in treatment.
• Do not attempt self‑injection unless specifically trained and cleared to do so by a clinician and in accordance with the product instructions.

Missed dose guidance
• If an injection appointment is missed, contact the prescribing clinic as soon as possible to reschedule; they will decide whether to give the dose promptly and adjust future dosing dates.
• Do not double doses or give extra injections without medical direction.

Overdose
• Symptoms may include more pronounced gastrointestinal upset, very slow heart rate, dizziness, or changes in blood sugar.
• In suspected overdose, seek immediate medical attention or contact poison control; management is supportive and based on symptoms.

Common side effects
• Very common: injection‑site pain, lumps, or induration; diarrhea, abdominal pain, nausea, vomiting, constipation, and gas; sometimes headache, dizziness, or fatigue.
• Many gastrointestinal effects appear in the first days to weeks of treatment and may lessen over time as the body adjusts.
• Most common effects are mild to moderate but can be bothersome; persistent or worsening symptoms should be discussed with a clinician.

Serious or rare adverse effects
• Gallbladder problems (gallstones, cholecystitis or biliary colic) due to reduced gallbladder motility; may present with right‑upper‑abdominal pain, fever, nausea, or jaundice and requires prompt medical evaluation.
• Changes in blood sugar, including both hyperglycemia and, less often, hypoglycemia; patients with diabetes may need adjustments in antidiabetic therapy.
• Pancreatitis (severe, persistent abdominal pain, often with nausea/vomiting), severe allergic reactions (rash, swelling of face/lips/tongue, trouble breathing), or significant slowing of heart rate or conduction disturbances are uncommon but need immediate medical attention.

Warnings and precautions
• Pregnancy: human data are limited; use only if clearly needed after a careful risk–benefit discussion.
• Breastfeeding: it is not known if lanreotide passes into breast milk; many guidelines recommend caution or avoiding breastfeeding or the drug, depending on clinical necessity.
• Use cautiously in patients with gallbladder disease, biliary tract disease, diabetes or prediabetes, pancreatitis history, or significant heart conduction abnormalities or bradycardia.
• Dose adjustment or closer monitoring may be needed in moderate to severe kidney or liver impairment, depending on the specific product labeling.

Safety compared with similar drugs
• Overall safety profile is similar to other long‑acting somatostatin analogs (such as octreotide LAR), with gastrointestinal symptoms, gallstones, and glucose changes as class effects.
• Injection‑site reactions may differ somewhat because of the deep subcutaneous route and prefilled syringe design, but serious systemic adverse effects are uncommon when monitored appropriately.

Side‑effect reporting and safety updates
• Patients and clinicians can report suspected side effects to the FDA MedWatch program or to the manufacturer’s safety line.
• Up‑to‑date safety communications and label changes are available on FDA and manufacturer websites.

Drug and supplement interactions
• Lanreotide can affect the absorption or action of other drugs whose levels depend on gastrointestinal motility, such as oral medications; clinicians may monitor and adjust dosing if needed.
• It may alter insulin and oral antidiabetic requirements because it changes growth hormone and glucagon secretion; close glucose monitoring is recommended when starting or changing dose in people with diabetes.
• Caution is advised with drugs that slow heart rate or affect cardiac conduction (for example, beta‑blockers, some calcium channel blockers, certain antiarrhythmics) because lanreotide itself can reduce heart rate.
• No specific food or alcohol interactions are unique to lanreotide, but alcohol may worsen gastrointestinal side effects in some patients.

Interactions with procedures
• Somatostatin analogs can interfere with certain diagnostic tests that measure hormone levels or rely on gastrointestinal motility; clinicians may time imaging or lab tests relative to injections when needed.
• In patients undergoing surgery or procedures, anesthesiologists should be aware of lanreotide therapy because of potential effects on heart rate, blood pressure, and glucose.

Precautions and contraindications
• Use cautiously in patients with known gallbladder disease, pancreatitis history, uncontrolled diabetes, severe heart conduction disorders, or significant bradycardia.
• Not recommended in patients with known serious hypersensitivity to lanreotide or other somatostatin analogs.
• Elderly patients or those with significant kidney or liver impairment may require dose adjustments and closer monitoring.

Monitoring needs
• Acromegaly: regular monitoring of growth hormone and IGF‑1 levels, as well as clinical symptoms.
• Neuroendocrine tumors: periodic imaging (CT/MRI or other appropriate scans) to assess tumor progression and response.
• All treated patients: periodic blood tests for liver function, blood sugar or A1c, thyroid function in some cases, and sometimes gallbladder ultrasound if symptoms arise or long‑term use is planned; clinicians may also monitor heart rate or perform ECGs in patients at cardiac risk.

Q: How often is lanreotide acetate injected and who gives the injection?
A: It is usually given as a deep subcutaneous injection every 4 weeks, most often by a healthcare professional, although some patients may be trained to receive injections at home if appropriate.

Q: How long does it take for lanreotide to start working?
A: Some improvement in hormone levels or symptoms can appear within weeks, but full benefits in acromegaly or neuroendocrine tumors often take several weeks to a few months of regular injections.

Q: Can lanreotide cure acromegaly or neuroendocrine tumors?
A: Lanreotide is not usually curative; it mainly controls hormone overproduction, improves symptoms, and can slow tumor growth, while surgery, radiation, or other therapies are sometimes needed for long‑term disease control.

Q: What are the most common side effects I should watch for?
A: Upset stomach, diarrhea or constipation, abdominal pain, injection‑site pain or lumps, and sometimes headache or fatigue are common; report persistent, severe, or new symptoms such as intense abdominal pain, jaundice, or very slow heartbeat promptly.

Q: Do I need to change my diabetes medicines when starting lanreotide?
A: Because lanreotide can affect blood sugar, people with diabetes often need closer glucose monitoring when starting or changing the dose, and adjustments to insulin or oral medications may be required under their clinician’s guidance.

Storage
• Keep prefilled syringes refrigerated at 36°F to 46°F (2°C to 8°C) in the original package, protected from light; do not freeze.
• If needed, the syringe may usually be kept at room temperature (not above about 77°F/25°C) for a limited time before use, following the product’s specific time limits, and should not be returned to the refrigerator once warmed.
• Keep out of reach of children.

Handling and disposal
• Do not use if the solution is discolored, contains particles, or the syringe is damaged or has been frozen.
• Dispose of used syringes, needles, and sharps immediately in an FDA‑cleared sharps disposal container; do not throw loose needles into household trash or recycling.
• Follow local or pharmacy guidance for disposing of full sharps containers and any unused or expired medication.